



***BioAlliance Pharma presents results for its new oral Irinotecan nanoparticle formulation for the treatment of advanced colorectal cancer at the American Association for Cancer Research (AACR) 100th Annual Meeting in Denver, April 18 to 22, 2009***

Paris, April 21st 2009 - BioAlliance Pharma SA (Euronext Paris - BIO), a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, has presented results for its oral Irinotecan nanoparticle formulation for the treatment of advanced colorectal cancer at the American Association for Cancer Research (AACR) 100th Annual Meeting, in Denver, April 18 to 22, 2009.

Colorectal cancer is the third leading cancer after prostate and breast cancer. Each year, over one million new cases are diagnosed worldwide. Colorectal cancer is also the second leading cause of cancer-related death.

One of the most common treatments for colorectal cancer is the combination of Irinotecan (Camptosar<sup>®</sup>) and Capecitabine (Xeloda<sup>®</sup>). Whereas Capecitabine is given orally (2 tablets a day during 14 days each 21 days), Irinotecan is still administered by intravenous route during 48 hours every 14 days.

Results presented at the AACR Meeting describe a new oral formulation of Irinotecan (IRN-SRN) encapsulated into nanoparticles allowing an oral release of the molecule. The aim of this new formulation is to combine a better tolerance to a sustained release of Irinotecan administered orally, thus increasing its efficacy.

Tested on animals, this new formulation orally administrated is well tolerated. Moreover, oral administration on animals bearing colorectal tumours is shown to induce a similar tumour growth inhibition to the one observed with Irinotecan administered intravenously, with a nearly 80% tumour growth inhibition.

### **About the American Association of Cancer Research (AACR)**

The mission of the AACR is to prevent and cure cancer through research, education, communication, and collaboration. Through its programs and services, the AACR fosters research in cancer and related biomedical science, accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer, promotes science education and training and advances the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

### **About BioAlliance Pharma**

As a preferred partner for hospital-based specialists, BioAlliance Pharma is a specialty biopharmaceutical company which develops and markets innovative products, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, our targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs.

For more information, visit the BioAlliance Pharma web site at <http://www.bioalliancepharma.com>.

### **Disclaimer**

*This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2008 Reference Document filed with the AMF on April 7, 2009, which is available on the AMF website (<http://www.amf-france.org>) or on BioAlliance Pharma S.A.'s website (<http://www.bioalliancepharma.com>).*

### **BioAlliance Pharma SA**

Dominique Costantini, President and CEO  
Tel.: +33 1 45 58 76 01  
[dominique.costantini@bioalliancepharma.com](mailto:dominique.costantini@bioalliancepharma.com)  
Nicolas Fellmann, CFO  
Tel.: +33 1 45 58 71 00  
[nicolas.fellmann@bioalliancepharma.com](mailto:nicolas.fellmann@bioalliancepharma.com)

### **ALIZE RP**

Caroline Carmagnol  
Tel.: +33 6 64 18 99 59  
[caroline@alizerp.com](mailto:caroline@alizerp.com)